A human Anti-matriptase-2 antibody limits iron overload, α-globin aggregates and splenomegaly in β-thalassemic mice
Matthew Stephen Wake,Anaïs Palin,Audrey Belot,Mathieu Berger,Megane Lorgouilloux,Margot Bichon,Jonathan Papworth,Luke Thomas Bayliss,Ben Grimshaw,Natalie Rynkiewicz,Jemima Paterson,Alicia Poindron,Erin Spearing,Emily Carter,Robyne Hudson,Millie Campbell,Verena Petzer,Céline Besson-Fournier,Chloé Latour,Amélie Largounez,Ophélie Goubeyre,Alexis Fay,Helene Coppin,Marie-Paule Roth,Igor Theurl,Volker Germaschewski,Delphine Meynard
DOI: https://doi.org/10.1182/bloodadvances.2023012010
IF: 7.642
2024-01-24
Blood Advances
Abstract:Iron plays a major role in the deterioration of β-thalassemia. Indeed, the high levels of transferrin saturation and iron delivered to erythroid progenitors are associated with production of α-globin precipitates that negatively affect erythropoiesis. Matriptase-2/TMPRSS6, a membrane-bound serine protease expressed in hepatocytes, negatively modulates hepcidin production and thus is a key target to prevent iron overload in β-thalassemia. To address safety concerns raised by the suppression of Tmprss6 by anti-sense oligonucleotides or small interfering RNA, we tested a fully human anti-matriptase-2 antibody, RLYB331, that blocks the protease activity of matriptase-2. When administered weekly to Hbb th3/+ mice, RLYB331 induced hepcidin expression, reduced iron loading, prevented the formation of toxic α-chain/heme aggregates, reduced ROS formation, and improved reticulocytosis and splenomegaly. To increase the effectiveness of RLYB331 in β-thalassemia treatment even further, we administered RLYB331 in combination with RAP-536L, a ligand-trapping protein that contains the extracellular domain of activin receptor type IIB and alleviates anemia by promoting differentiation of late-stage erythroid precursors. RAP-536L alone did not prevent iron overload but significantly reduced apoptosis in the erythroid populations of the bone marrow, normalized red blood cell counts and improved hemoglobin and hematocrit levels. Interestingly, the association of RLYB331 with RAP-536L entirely reversed the β-thalassemia phenotype in Hbb th3/+ mice and simultaneously corrected iron overload, ineffective erythropoiesis, splenomegaly and hematological parameters, suggesting that a multi-functional molecule consisting of the fusion of RLYB331 with Luspatercept (human version of RAP-536L) would allow administration of a single medication addressing simultaneously the different pathophysiological aspects of β-thalassemia.
hematology